Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The company's management will present a corporate update available on demand from August 15, 2024, at 7:00 a.m. ET.
Additionally, Dr. Victor Chong, Chief Medical Officer, will take part in a panel discussion on the Evolving Therapeutic Landscape of AMD. Interested parties can access the live and archived webcast presentation through the Investors section of Clearside's website under Events and Presentations.
Clearside Biomedical (Nasdaq: CLSD), un'azienda biofarmaceutica specializzata nella somministrazione di terapie per la parte posteriore dell'occhio attraverso lo spazio suprachoroidale (SCS®), ha annunciato la sua partecipazione al 4° Conferenza Virtuale Annuale di Oftalmologia H.C. Wainwright. La direzione dell'azienda presenterà un aggiornamento aziendale disponibile on demand a partire dal 15 agosto 2024, alle 7:00 ET.
Inoltre, Dr. Victor Chong, Direttore Medico, parteciperà a una tavola rotonda sulla Evoluzione del Paesaggio Terapeutico dell'AMD. Le parti interessate possono accedere alla presentazione in diretta e a quella archiviata tramite la sezione Investitori del sito web di Clearside, nella sezione Eventi e Presentazioni.
Clearside Biomedical (Nasdaq: CLSD), una empresa biofarmacéutica especializada en ofrecer terapias para la parte posterior del ojo a través del espacio supracoroideo (SCS®), ha anunciado su participación en la 4ª Conferencia Virtual Anual de Oftalmología H.C. Wainwright. La dirección de la empresa presentará una actualización corporativa disponible bajo demanda a partir del 15 de agosto de 2024, a las 7:00 a.m. ET.
Además, Dr. Victor Chong, Director Médico, participará en una mesa redonda sobre el Panorama Terapéutico Evolutivo de la AMD. Los interesados pueden acceder a la presentación webcast en vivo y a la grabada a través de la sección de Inversores en el sitio web de Clearside, en la sección de Eventos y Presentaciones.
Clearside Biomedical (Nasdaq: CLSD)는 눈 뒤쪽에 치료제를 전달하는 것을 전문으로 하는 생명과학 회사이며, 슈프라코로이드 공간(SCS®)을 통해 치료제를 제공합니다. 이 회사는 H.C. Wainwright 제4회 연례 가상 안과학 컨퍼런스에 참가할 것이라고 발표했습니다. 회사 경영진은 2024년 8월 15일 오전 7시 ET부터 주문형으로 제공되는 기업 업데이트를 발표할 예정입니다.
또한, Dr. Victor Chong 최고 의료 책임자가 AMD의 진화하는 치료 환경에 대한 패널 토론에 참여할 것입니다. 관심 있는 분들은 Clearside의 웹사이트 투자자 섹션의 이벤트 및 발표에서 라이브와 아카이브된 웹캐스트 프레젠테이션에 접근할 수 있습니다.
Clearside Biomedical (Nasdaq: CLSD), une entreprise biopharmaceutique spécialisée dans l'administration de thérapies à l'arrière de l'œil à travers l'espace suprachoroïdien (SCS®), a annoncé sa participation à la 4ème Conférence Virtuelle Annuelle d'Ophthalmologie H.C. Wainwright. La direction de l'entreprise présentera une mise à jour de l'entreprise disponible à la demande à partir du 15 août 2024, à 7h00 ET.
De plus, Dr. Victor Chong, Directeur Médical, participera à une discussion en panel sur le Paysage Thérapeutique Évolutif de la DMLA. Les parties intéressées peuvent accéder à la présentation en direct et archivée via la section Investisseurs du site web de Clearside dans la section Événements et Présentations.
Clearside Biomedical (Nasdaq: CLSD), ein biopharmazeutisches Unternehmen, das sich auf die Bereitstellung von Therapien für den hinteren Teil des Auges durch den suprachoroidalen Raum (SCS®) spezialisiert hat, hat seine Teilnahme an der 4. jährlichen virtuellen Augenheilkunde-Konferenz von H.C. Wainwright angekündigt. Das Management des Unternehmens wird ein Firmenupdate präsentieren, das ab 15. August 2024, um 7:00 Uhr ET auf Abruf verfügbar sein wird.
Zusätzlich wird Dr. Victor Chong, Chief Medical Officer, an einer Podiumsdiskussion über die Entwicklung der therapeutischen Landschaft der AMD teilnehmen. Interessierte Parteien können die Live- und Archivpräsentation über den Investorenbereich der Clearside-Website unter Veranstaltungen und Präsentationen abrufen.
- None.
- None.
ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that management will present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference which will be available on demand on Thursday, August 15, 2024, at 7:00 a.m. ET. Victor Chong, MD, MBA, Chief Medical Officer, will also participate in a panel discussion on the Evolving Therapeutic Landscape of AMD.
A link to the live and archived webcast presentation may be accessed on the Clearside website under the Investors section: Events and Presentations.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com and follow us on LinkedIn and X.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
When is Clearside Biomedical (CLSD) presenting at the H.C. Wainwright Ophthalmology Conference?
What is Clearside Biomedical's (CLSD) area of expertise?
Who from Clearside Biomedical (CLSD) is participating in the AMD panel discussion?
How can investors access Clearside Biomedical's (CLSD) presentation at the H.C. Wainwright conference?
